<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39285602</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-3083</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Scandinavian journal of immunology</Title><ISOAbbreviation>Scand J Immunol</ISOAbbreviation></Journal><ArticleTitle>No signs of mast cell involvement in long-COVID: A&#xa0;case-control study.</ArticleTitle><Pagination><StartPage>e13407</StartPage><MedlinePgn>e13407</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/sji.13407</ELocationID><Abstract><AbstractText>Long-COVID caused by SARS-CoV-2 infection has significant and increasing effects on human health worldwide. Although a unifying molecular or biological explanation is lacking, several pathophysiological mechanisms have been proposed. Involvement of mast cells-evolutionary old "multipurpose" innate immune cells-was reported recently in studies of acute infection and post-acute-COVID-19 syndrome. Mast cell activity has been suggested in long-COVID. In this case-control study, we compared data from 24 individuals with long-COVID (according to the NICE criteria) and 24 age- and sex-matched healthy individuals with a history of SARS-CoV-2 infection without developing sequelae. Serum levels of the proteases beta-tryptase (TPSB2) and carboxypeptidase (CPA3), which are mast cell specific, were measured using immunoassays. The values were compared between the two groups and correlated to measures of physical exertional intolerance. TPSB2 and CPA3 levels were median (range) 26.9 (2.0-1000) and 5.8 (1.5-14.0) ng/mL, respectively, in the long-COVID group. The corresponding values in the control group were 10.9 (2.0-1000) (p&#x2009;=&#x2009;0.93) and 5.3 (3.5-12.9) ng/mL (p&#x2009;=&#x2009;0.82). No significant correlations between TPSB2 or CPA3 levels and scores on the ten physical subscales of SF-36, 3.1-3.10 were revealed. We found no significant differences in the levels of mast cell activation markers TPSB2 and CPA3 between the long-COVID and control groups and no correlations with proxy markers of exercise intolerance. Mast cell activation does not appear to be part of long-term pathogenesis of long-COVID, at least in the majority of patients.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Scandinavian Journal of Immunology published by John Wiley &amp; Sons Ltd on behalf of The Scandinavian Foundation for Immunology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lenning</LastName><ForeName>Ole Bernt</ForeName><Initials>OB</Initials><Identifier Source="ORCID">0000-0002-0917-5806</Identifier><AffiliationInfo><Affiliation>Research Department, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jonsson</LastName><ForeName>Grete</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimstad</LastName><ForeName>Tore</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janssen</LastName><ForeName>Emiel A M</ForeName><Initials>EAM</Initials><AffiliationInfo><Affiliation>Department of Pathology, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braut</LastName><ForeName>Geir Sverre</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0002-3337-4792</Identifier><AffiliationInfo><Affiliation>Research Department, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Social Science, Western Norway University of Applied Sciences, Sogndal, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berven</LastName><ForeName>Frode</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Proteomics Unit of the University of Bergen, Department of Biomedicine, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Omdal</LastName><ForeName>Roald</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6051-4658</Identifier><AffiliationInfo><Affiliation>Research Department, Stavanger University Hospital, Stavanger, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Science, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SDAM_HEL45920</GrantID><Agency>EkstraStiftelsen Helse og Rehabilitering (Stiftelsen Dam)</Agency><Country/></Grant><Grant><Agency>Norwegian Brain Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Scand J Immunol</MedlineTA><NlmUniqueID>0323767</NlmUniqueID><ISSNLinking>0300-9475</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.59</RegistryNumber><NameOfSubstance UI="D053802">Tryptases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.1</RegistryNumber><NameOfSubstance UI="D043422">Carboxypeptidases A</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.1</RegistryNumber><NameOfSubstance UI="C468648">CPA3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.59</RegistryNumber><NameOfSubstance UI="C546348">TPSAB1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008407" MajorTopicYN="Y">Mast Cells</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053802" MajorTopicYN="Y">Tryptases</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043422" MajorTopicYN="Y">Carboxypeptidases A</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">exertional intolerance</Keyword><Keyword MajorTopicYN="N">long&#x2010;COVID</Keyword><Keyword MajorTopicYN="N">mast cells</Keyword><Keyword MajorTopicYN="N">mast cell&#x2010;derived proteases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>0</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39285602</ArticleId><ArticleId IdType="doi">10.1111/sji.13407</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23(10):618&#x2010;634.</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2010;146.</Citation></Reference><Reference><Citation>FAIR Health. Patients diagnosed with post&#x2010;COVID conditions: an analysis of private healthcare claims using the official ICD&#x2010;10 diagnostic code (FAIR Health, 2022). Patients Diagnosed with Post&#x2010;COVID Conditions &#x2010; A FAIR Health White Paper.pdf. Published May 18, 2022. Accessed January 31, 2022.</Citation></Reference><Reference><Citation>Umesh A, Pranay K, Pandey RC, Gupta MK. Evidence mapping and review of long&#x2010;COVID and its underlying pathophysiological mechanism. Infection. 2022;50(5):1053&#x2010;1066.</Citation></Reference><Reference><Citation>Dahlin JS, Maurer M, Metcalfe DD, Pejler G, Sagi&#x2010;Eisenberg R, Nilsson G. The ingenious mast cell: contemporary insights into mast cell behavior and function. Allergy. 2022;77(1):83&#x2010;99.</Citation></Reference><Reference><Citation>Vikse J, Omdal R. Fatigue in mastocytosis: a case series. Clin Ther. 2019;41(4):625&#x2010;632.</Citation></Reference><Reference><Citation>Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA. Mast cell activation is associated with post&#x2010;acute COVID&#x2010;19 syndrome. Allergy. 2022;77(4):1288&#x2010;1291.</Citation></Reference><Reference><Citation>Wang LN, Wang XZ, Li YJ, et&#xa0;al. Activation of subcutaneous mast cells in acupuncture points triggers analgesia. Cells. 2022;11(5):809.</Citation></Reference><Reference><Citation>COVID&#x2010;19 rapid guideline: managing the long&#x2010;term effects of COVID&#x2010;19. Published December 18, 2020. Accessed January 25, 2024. https://www.nice.org.uk/guidance/ng188/chapter/1&#x2010;Identification</Citation></Reference><Reference><Citation>Ware JE, Sherbourne CD. The MOS 36&#x2010;item short&#x2010;form health survey (SF&#x2010;36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473&#x2010;483.</Citation></Reference><Reference><Citation>Gebremeskel S, Schanin J, Coyle KM, et&#xa0;al. Mast cell and eosinophil activation are associated with COVID&#x2010;19 and TLR&#x2010;mediated viral inflammation: implications for an anti&#x2010;Siglec&#x2010;8 antibody. Front Immunol. 2021;12:650331.</Citation></Reference><Reference><Citation>Soria&#x2010;Castro R, Meneses&#x2010;Preza YG, Rodr&#xed;guez&#x2010;L&#xf3;pez GM, et&#xa0;al. Severe COVID&#x2010;19 is marked by dysregulated serum levels of carboxypeptidase A3 and serotonin. J Leukoc Biol. 2021;110(3):425&#x2010;431.</Citation></Reference><Reference><Citation>McManimen SL, Jason LA. Post&#x2010;exertional malaise in patients with ME and CFS with comorbid fibromyalgia. SRL Neurol Neurosurg. 2017;3(1):22&#x2010;27.</Citation></Reference><Reference><Citation>Twomey R, Yeung ST, Wrightson JG, Millet GY, Culos&#x2010;Reed SN. Post&#x2010;exertional malaise in people with chronic cancer&#x2010;related fatigue. J Pain Symptom Manage. 2020;60(2):407&#x2010;416.</Citation></Reference><Reference><Citation>Appelman B, Charlton BT, Goulding RP, et&#xa0;al. Muscle abnormalities worsen after post&#x2010;exertional malaise in long COVID. Nat Commun. 2024;15(1):17.</Citation></Reference><Reference><Citation>Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12(2):123&#x2010;137.</Citation></Reference><Reference><Citation>Dantzer R, Heijnen C, Kavelaars A, Laye S, Capuron L. The neuroimmune basis of fatigue. Trends Neurosci. 2014;37(1):39&#x2010;46.</Citation></Reference><Reference><Citation>Kvivik I, Grimstad T, B&#xe5;rdsen K, Jonsson G, Kval&#xf8;y JT, Omdal R. High mobility group box&#xa0;1 and a network of other biomolecules influence fatigue in patients with Crohn's disease. Mol Med. 2023;29:81.</Citation></Reference><Reference><Citation>B&#xe5;rdsen K, Brede C, Kvivik I, et&#xa0;al. Interleukin&#x2010;1&#x2010;related activity and hypocretin&#x2010;1 in cerebrospinal fluid contribute to fatigue in primary Sj&#xf6;gren's syndrome. J Neuroinflammation. 2019;16:102.</Citation></Reference><Reference><Citation>Bannister BA. Post&#x2010;infectious disease syndrome. Postgrad Med J. 1988;64(753):559&#x2010;567.</Citation></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, et&#xa0;al. Post&#x2010;infective and chronic fatigue syndromes precipitated by viral and non&#x2010;viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575.</Citation></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post&#x2010;acute infection syndromes. Nat Med. 2022;28(5):911&#x2010;923.</Citation></Reference><Reference><Citation>Dantzer R. Evolutionary aspects of infections: inflammation and sickness behaviors. Curr Top Behav Neurosci. 2023;61:1&#x2010;14.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>